Global Bipolar Disorder Treatment Market - Industry Trends and Forecast to 2030

Bipolar Disorder Treatment Market Analysis and Size

Bipolar disorder is a chronic mental health condition characterized by extreme mood swings, including manic and depressive episodes. The global bipolar disorder treatment market includes various pharmaceuticals, psychotherapies, and other interventions aimed at managing and alleviating the symptoms of the disorder. The use of digital health technologies, telemedicine, and mobile apps for mental health monitoring and management has expanded treatment options and increased patient engagement.

Data Bridge Market Research analyses that the global bipolar disorder treatment market which was USD 5,200.00 million in 2022, expected to reach USD 6,410.25 million by 2030, and is expected to undergo a CAGR of 2.6% during the forecast period 2023-2030. This indicates the market value. “Bipolar I” dominates the bipolar disorders type segment of the global bipolar disorder treatment market owing to the growing demand for better methods of bone related treatment. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Bipolar Disorder Treatment Market Scope and Segmentation

Market Definition

The global bipolar disorder treatment market is the collective pharmaceuticals, therapies, and interventions aimed at managing and alleviating the symptoms and effects of bipolar disorder on a worldwide scale. Bipolar disorder, also known as manic-depressive illness, is a mental health condition characterized by extreme mood swings, including episodes of mania (elevated, high-energy mood) and depression (low, sad, or irritable mood). These mood swings can significantly impact a person's daily life, relationships, and overall well-being.

Global Bipolar Disorder Treatment Market Dynamics

Drivers

• Increasing Prevalence of Bipolar Disorder

The growing awareness and diagnosis of bipolar disorder have contributed to the expansion of the treatment market. Improved recognition of the condition has led to a higher demand for treatments.

• Advancements in Drug Development

Pharmaceutical companies have been actively investing in research and development to create more effective and targeted drugs for bipolar disorder. New drug formulations with fewer side effects and improved efficacy have emerged, attracting both patients and healthcare professionals.

Opportunity

• Increasing Healthcare Expenditure

As healthcare spending continues to rise in many countries, there is more financial support available for the diagnosis and treatment of mental health conditions, including bipolar disorder.

Restraint/Challenge

• Limited Access to Care

Disparities in access to mental healthcare, including shortages of mental health professionals and treatment facilities, can hinder timely and effective treatment for individuals with bipolar disorder, particularly in underserved areas.

Recent Development

• In September 2022, Otsuka America Pharmaceutical, Inc., (Otsuka) and H.Lundbeck A/S (Lundbeck) announced that the U.S. FDA approved their New Drug Application (NDA) for aripiprazole 2-month, ready-to-use, long-acting injectable, a medication administered for the treatment of bipolar I disorder in adults. This approval helped the company to expand their customer base

Global Bipolar Disorder Treatment Market  Scope

The global bipolar disorder treatment market is segmented on the basis of bipolar disorder type, drug class, mechanism of action, route of administration, distribution channel and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Bipolar Disorders Type

• Bipolar I
• Bipolar II

Drug Class

• Anticonvulsants
• Antianxiety
• Mood Stabilizers
• Antipsychotic
• Antidepressant
• Others

Mechanism of Action

• Selective Serotonin Reuptake Inhibitor
• Serotonin Norepinephrine Reuptake Inhibitors
• Tricyclic Antidepressants
• Monoamine Oxidase Inhibitors
• Benzodiazepines
• Beta Blockers

Route of Administration

• Oral
• Parenteral
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Bipolar Disorder Treatment Market Regional Analysis/Insights

The global bipolar disorder treatment market is analysed and market size insights and trends are provided by country, bipolar disorder type, drug class, mechanism of action, route of administration, distribution channel and end user as referenced above.

The countries covered in the global bipolar disorder treatment market report are U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa

North America dominates the bone global bipolar disorder treatment market because of the strong base of healthcare facilities, the strong presence of major players in the market, the extraordinary healthcare infrastructure, and the large pool of people having bipolar disorders. 

Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote healthcare, the rising health awareness among the people and growing demand for advanced medical technology for skin care, the large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.  

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The global bipolar disorder treatment market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the global bipolar disorder treatment market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on global bipolar disorder treatment market.

Competitive Landscape and Global Bipolar Disorder Treatment Market Share Analysis

The global bipolar disorder treatment market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the global bipolar disorder treatment market.

Some of the major players operating in the global bipolar disorder treatment market are:

• Johnson & Johnson Services, Inc.(U.S.)
• AbbVie Inc.(U.S.)
• Allergan (Ireland)
• Mallinckrodt (Ireland)
• Sun Pharmaceutical Industries Ltd.(India)
• Novartis AG (Switzerland)
• Endo Pharmaceuticals plc (Ireland)
• Zydus Cadila (India)
• Mylan N.V.(U.S.)
• Mayne Pharma Group Limited (Australia)
• Teva Pharmaceutical Industries Ltd (Israel)
• Amneal Pharmaceutical Inc.(U.S.)
• Avet Pharmaceuticals Inc.(U.S.)
• Lannett (U.S.)
• Aurobindo Pharma (India)
• Wockhardt (India)
• Currax Pharmaceuticals LLC (U.S.)
• AstraZeneca (U.K.)
• F. Hoffmann-La Roche Ltd.(Switzerland)
• Eli Lilly and Company (U.S.)

SKU-26466